(Q42550256)

2 November 2017

0 references

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials (English)

1 reference

2 November 2017

0 references

1 reference

1 reference

F Song

1

1 reference

PubMed ID

9097896

2 November 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

Journal of Psychopharmacology

2 November 2017

1 reference

2 November 2017

11

1 reference

2 November 2017

1

1 reference

2 November 2017

65-71

1 reference

Positive vs. negative schizophrenia: a critical evaluation

2 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone: review and assessment of its role in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

A risk-benefit assessment of risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Antipsychotic drugs: clinical pharmacology and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Combining estimates of the odds ratio: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Psychopharmacologic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Can meta-analyses be trusted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

Risperidone: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988119701100116

10.1177/026988119701100116

21 January 2018

Identifiers

DOI

0 references

PubMed ID

9097896

1 reference

PubMed ID

9097896